IN191496B - - Google Patents

Info

Publication number
IN191496B
IN191496B IN1036DE1999A IN191496B IN 191496 B IN191496 B IN 191496B IN 1036DE1999 A IN1036DE1999 A IN 1036DE1999A IN 191496 B IN191496 B IN 191496B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Yatendra Kumar
Rakesh Kumar Arora
Kaptan Singh
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Priority to IN1036DE1999 priority Critical patent/IN191496B/en
Priority to CN00812246A priority patent/CN1371381A/zh
Priority to PCT/IB2000/001024 priority patent/WO2001009143A1/en
Priority to BR0012865-1A priority patent/BR0012865A/pt
Priority to AU58391/00A priority patent/AU5839100A/en
Priority to JP2001513950A priority patent/JP2003506329A/ja
Priority to US10/048,354 priority patent/US6602999B1/en
Priority to EP00944159A priority patent/EP1204667A4/en
Priority to ZA200200692A priority patent/ZA200200692B/en
Publication of IN191496B publication Critical patent/IN191496B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN1036DE1999 1999-07-30 1999-07-30 IN191496B (OSRAM)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IN1036DE1999 IN191496B (OSRAM) 1999-07-30 1999-07-30
CN00812246A CN1371381A (zh) 1999-07-30 2000-07-24 改进的无定形头孢泊肟酯
PCT/IB2000/001024 WO2001009143A1 (en) 1999-07-30 2000-07-24 An improved amorphous form of cefpodoxime proxetil
BR0012865-1A BR0012865A (pt) 1999-07-30 2000-07-24 Uma forma amorfa aperfeiçoada da proxetil cefpodoxima
AU58391/00A AU5839100A (en) 1999-07-30 2000-07-24 An improved amorphous form of cefpodoxime proxetil
JP2001513950A JP2003506329A (ja) 1999-07-30 2000-07-24 セフポドキシメプロキセチルの改良アモルファス形態
US10/048,354 US6602999B1 (en) 1999-07-30 2000-07-24 Amorphous form of cefpodoxime proxetil
EP00944159A EP1204667A4 (en) 1999-07-30 2000-07-24 AN IMPROVED AMORPHE FORM OF CEFPODOXIM PROXETIL
ZA200200692A ZA200200692B (en) 1999-07-30 2002-01-25 An improved amorphous form of cefpodoxime proxetil.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1036DE1999 IN191496B (OSRAM) 1999-07-30 1999-07-30

Publications (1)

Publication Number Publication Date
IN191496B true IN191496B (OSRAM) 2003-12-06

Family

ID=11092065

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1036DE1999 IN191496B (OSRAM) 1999-07-30 1999-07-30

Country Status (9)

Country Link
US (1) US6602999B1 (OSRAM)
EP (1) EP1204667A4 (OSRAM)
JP (1) JP2003506329A (OSRAM)
CN (1) CN1371381A (OSRAM)
AU (1) AU5839100A (OSRAM)
BR (1) BR0012865A (OSRAM)
IN (1) IN191496B (OSRAM)
WO (1) WO2001009143A1 (OSRAM)
ZA (1) ZA200200692B (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT408226B (de) * 1999-05-05 2001-09-25 Biochemie Gmbh Kristalliner 7-(2-(2-formylaminothiazol-4-yl)-2
US7045618B2 (en) 2001-02-27 2006-05-16 Ranbaxy Laboratories Limited Cefpodixime proxetil
JP2007515430A (ja) * 2004-10-18 2007-06-14 テバ ファーマシューティカル インダストリーズ リミティド アルコール及びケトン、及び／又はエステルの混合物である有機溶媒に塩を溶解し、そして溶媒を除去することにより非晶質アトルバスタチンへミ−カルシウムの調製方法
US20090269400A1 (en) * 2005-05-16 2009-10-29 Elan Pharma International Limited Nanoparticulate and Controlled Release Compositions Comprising a Cephalosporin
KR100840132B1 (ko) * 2007-04-17 2008-06-23 재단법인서울대학교산학협력재단 포화 액체 이산화탄소를 사용한 세포독심 프록세틸의 건조
EA033374B9 (ru) * 2012-09-11 2019-12-18 Медивейшн Простейт Терапьютикс Ллк Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
JP2015534550A (ja) * 2012-09-11 2015-12-03 ドクター レディズ ラボラトリーズ リミテッド エンザルタミドの多形形態およびその調製
HK1247829A1 (zh) 2015-03-06 2018-10-05 Atea Pharmaceuticals, Inc. 用於治疗HCV的β-D-2'-脱氧-2'Α-氟-2'-β-C-取代-2-改性N6-取代的嘌呤核苷酸
WO2017046756A1 (en) * 2015-09-18 2017-03-23 Lupin Limited Proxetil and axetil esters of cefixime
MX380022B (es) * 2016-05-09 2025-03-11 Anacor Pharmaceuticals Inc Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
WO2017218957A1 (en) * 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Solid state forms of spiro-oxindole compounds
US10717715B2 (en) * 2016-09-06 2020-07-21 Indena S.P.A. Solid forms of ingenol 3-(3,5-diethylisoxazole-4-carboxylate) and method for preparing the same
EP3512863B1 (en) 2016-09-07 2021-12-08 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
EP4450129A3 (en) * 2017-02-01 2025-03-19 ATEA Pharmaceuticals, Inc. Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
IL269667B2 (en) * 2017-03-30 2024-09-01 Merck Patent GmbH Solid forms of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl) methanol, its preparation and pharmaceutical compositions containing them
TWI808108B (zh) * 2017-11-22 2023-07-11 美商阿吉歐斯製藥公司 N-(4-(4-(環丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺醯胺之結晶型
BR112020020246A8 (pt) * 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
TW202012001A (zh) 2018-04-10 2020-04-01 美商亞堤製藥公司 C型肝炎病毒(hcv)感染硬化之患者的治療
CN110251467A (zh) * 2019-06-26 2019-09-20 北京济美堂医药研究有限公司 一种无定形态头孢妥仑匹酯组合物的制备方法
CN110437259B (zh) * 2019-08-14 2021-12-07 中国药科大学 头孢泊肟酯柚皮素共无定形物及其制备方法
WO2021067772A1 (en) * 2019-10-04 2021-04-08 Sumitomo Dainippon Pharma Oncology, Inc. Axl inhibitor formulations
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
CN117500494A (zh) 2021-06-17 2024-02-02 阿堤亚制药公司 有利的抗hcv联合疗法
CN119256126A (zh) 2022-05-23 2025-01-03 国立大学法人名古屋工业大学 用湿式纺丝法连续制造包含无机填料粒子的生物降解性纤维材料的方法、以及用该方法制造的棉絮状的骨再生材料

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223153A (en) 1979-02-09 1980-09-16 Eli Lilly And Company Crystalline forms of N-2-(6-methoxy)benzothiazolyl N'-phenyl urea
IT1165253B (it) 1979-07-12 1987-04-22 Blasinachim Spa Procedimento di fabbricazione di acido chenodesossicolico cristallino puro
US4486425A (en) * 1980-09-30 1984-12-04 Sankyo Company Limited 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
PT531875E (pt) * 1991-09-07 2004-08-31 Aventis Pharma Gmbh Diastereomeros do ester 1-(isopropoxicarboniloxi)-etilico do acido 3-cefem-4-carboxilico e processo para a sua preparacao
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
AT413383B (de) * 1998-01-09 2006-02-15 Sandoz Ag Verfahren zur isolierung eines diastereoisomerengemisches von cefpodoxim proxetil
KR100342943B1 (ko) * 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물

Also Published As

Publication number Publication date
AU5839100A (en) 2001-02-19
BR0012865A (pt) 2002-07-09
EP1204667A1 (en) 2002-05-15
ZA200200692B (en) 2003-05-28
CN1371381A (zh) 2002-09-25
JP2003506329A (ja) 2003-02-18
EP1204667A4 (en) 2002-10-30
WO2001009143A1 (en) 2001-02-08
US6602999B1 (en) 2003-08-05

Similar Documents

Publication Publication Date Title
BE2014C017I2 (OSRAM)
BE2013C051I2 (OSRAM)
BE2013C020I2 (OSRAM)
BE2013C015I2 (OSRAM)
BE2013C001I2 (OSRAM)
BE2012C036I2 (OSRAM)
BE2008C046I2 (OSRAM)
BE1025464I2 (OSRAM)
BE2010C011I2 (OSRAM)
JP2002507757A5 (OSRAM)
JP2002502043A5 (OSRAM)
JP2002521141A5 (OSRAM)
BE2008C047I2 (OSRAM)
BE2011C004I2 (OSRAM)
JP2000286458A5 (OSRAM)
IN191496B (OSRAM)
JP2002525223A5 (OSRAM)
JP2002528905A5 (OSRAM)
JP2002526310A5 (OSRAM)
IN187487B (OSRAM)
IN187119B (OSRAM)
IN186577B (OSRAM)
FR2776171A3 (OSRAM)
CN3098953S (OSRAM)
CN3097870S (OSRAM)